Nathaniel Lipkus Nathaniel Lipkus

The nascent CRISPR-Cas9 patent landscape in Canada

CRISPR-Cas9 is a transformative technology with the potential for unimaginable impact. However, two academic groups have been engaged in a...

Canada’s IP strategy is inspired, but will it inspire innovators?

Why are we so bad at capturing IP in Canada? Because only in rare cases have Canadian business successes been driven by IP, and as a result, IP is...

Welcome to the Canadian pharmaceutical patent dance

For nearly 25 years, Canada’s Patented Medicines (Notice of Compliance) Regulations have been the cornerstone of pharmaceutical patent litigation...

Canada’s patent linkage regulations get long-awaited makeover

On July 15, 2017, the Government of Canada proposed major amendments to the Patented Medicines (Notice of Compliance) Regulations, the patent linkage...

Major U.S. court decisions change patent landscape for Canadian companies

A pair of recent U.S. Supreme Court decisions in patent cases have the potential to alter the risk landscape for cross-border commercialization.

IP 101 for Emerging Companies: Protecting Your Ideas Your Way

Join Nathaniel Lipkus of Osler's Intellectual Property Team for an insightful webinar on key issues surrounding intellectual property strategy.

Canada’s NAFTA arbitration victory is a win for sovereignty and fair trade

President Trump beat up on NAFTA to secure votes in the US election. Now that he is President, he has put the trade agreement on the chopping block,...

Federal Court ruling exposes difficulty of reversing Health Canada scientific decisions

On February 1, 2017, the Federal Court of Canada upheld Health Canada’s denial of approval of a generic hormone replacement product (progesterone)...

First-ever judgment on Canadian information technology patent signals caution for owners of broad patents

In January 2017, the Federal Court found in MediaTube v Bell that Bell’s IPTV does not infringe a Canadian patent, signalling to information...

Reversal of $200-million drug patent verdict offers hard lessons for technology collaborators

On June 6, 2016, a U.S. District Court judge overturned the damages verdict in Gilead Sciences Inc. v. Merck & Co, holding that Merck’s patents...